Welcome to our dedicated page for Inotiv SEC filings (Ticker: NOTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inotiv, Inc. filings document the regulatory record of an operating contract research organization with Discovery and Safety Assessment and Research Models and Services operations. Current reports furnish financial results and business updates, including segment-related discussion for nonclinical and analytical drug development services, research models, and related products.
Material-event filings also describe credit-agreement administration, including waivers tied to minimum liquidity covenants, Nasdaq listing-compliance notices, shareholder voting matters, and governance disclosures. The filings provide formal records of capital-structure obligations, operating results, risk-related events, and public-company compliance matters for NOTV common stock.
Inotiv, Inc. Chief Strategy Officer John E. Sagartz reported an automatic sale of company stock to cover taxes on vested restricted stock units. On this transaction date, 2,119 shares of common stock were sold at an average price of $0.2908 per share under a pre-set Rule 10b5-1 instruction. Following this tax-withholding sale, Sagartz directly held 735,697 shares of Inotiv common stock.
Inotiv, Inc. President and CEO Robert Jr. Leasure reported an automatic sale of 16,810 shares of common stock on February 17, 2026. The shares were sold by the company on his behalf to cover tax withholding when restricted stock units vested, under a Rule 10b5-1 instruction entered between September 11 and October 9, 2024.
The weighted average sale price was about $0.2953 per share, with individual trades between $0.29 and $0.30. After this transaction, he directly holds 1,256,215 common shares. An additional 105,000 shares are held by an entity in which he is the majority security holder, and he disclaims ownership except for his economic interest.
Inotiv Inc. insider filing outlines planned stock sales under Rule 144. The notice covers up to 20,000 shares of common stock to be sold through Raymond James & Associates on or about February 17, 2026 on the NASDAQ, with an aggregate market value of $5,800 and total shares outstanding of 34,390,000.
The seller previously acquired 55,000 common shares on February 16, 2026 via an RSU grant from the issuer, with cash payment dated February 17, 2026. During the prior three months, the filer, Robert Leasure, sold 113,297 common shares on February 6, 2026 for gross proceeds of $56,216.
Inotiv, Inc. reported quarterly revenue of $120.9M for the three months ended December 31, 2025, roughly flat year over year, but posted an operating loss of $16.3M and a net loss of $28.4M or $0.83 per share. Cash and cash equivalents fell to $12.7M from $21.7M at September 30, 2025, while net cash used in operating activities was $5.4M.
Total assets were $734.3M against total liabilities of $625.3M, including $413.6M of debt, all classified as current because of covenant risk and maturities within 12 months. Management discloses substantial doubt about the company’s ability to continue as a going concern due to expected covenant noncompliance and upcoming term loan, revolver, convertible note and second-lien note maturities, and is pursuing cost controls and potential refinancing with no assurance of success.
Inotiv, Inc. reported first quarter fiscal 2026 results showing nearly flat revenue but continued losses. Revenue for the three months ended December 31, 2025 was $120.9 million, up 0.8% from $119.9 million a year earlier. Discovery & Safety Assessment revenue grew 12.0% to $48.0 million, while Research Models & Services revenue declined 5.4% to $72.9 million, mainly from lower non-human primate volumes.
Operating loss increased to $16.3 million from $15.5 million, and consolidated net loss widened slightly to $28.4 million. Adjusted EBITDA was $1.8 million, or 1.5% of revenue, compared with $2.6 million, or 2.2%, in the prior-year quarter. Cash and cash equivalents declined to $12.7 million at December 31, 2025 from $21.7 million at September 30, 2025, while total debt was $405.8 million. For the DSA services business, the book-to-bill ratio was 1.16x and backlog rose to $145.4 million, indicating growing contracted work despite current losses.
Inotiv President and CEO Robert Leasure Jr. had 113,297 shares of common stock automatically sold on February 2, 2026 at a weighted average price of $0.5034 per share to satisfy tax withholding obligations on vested restricted stock units.
Following this sell-to-cover transaction, he directly beneficially owned 1,273,025 common shares. An additional 105,000 shares are held by an entity for which he is the majority security holder, and he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
A holder of NOTV common stock has filed a notice of proposed sale under Rule 144. The filer plans to sell 120,000 shares through Raymond James & Associates on or about 02/02/2026 on the NASDAQ market, with an aggregate market value of $59,088.00. The issuer had 34,400,000 shares outstanding. The securities to be sold are part of a 300,000-share RSU grant of common stock acquired on 02/01/2026, with cash payment dated 02/02/2026.
Inotiv, Inc. files an amended annual report to add detailed Part III information on directors, executive compensation, ownership and auditor fees, without revising previously reported financial results. The filing describes a largely independent board with a separate, independent chair and CEO roles.
For fiscal 2025, executives received base salary increases and significant stock-based incentives, but no annual cash bonuses were paid despite approved bonus targets. CEO total compensation was $2,941,549, and the CEO pay ratio was 50:1 versus a median employee at $58,998. Directors and executives as a group beneficially owned about 10.7% of common shares.
Inotiv, Inc. reported that a federal court has issued a preliminary approval order for a proposed settlement of consolidated stockholder derivative actions in federal and Indiana state court. Under the proposed settlement, the company will implement certain corporate governance measures and receive a $2,490,000 payment for its benefit funded entirely by available insurance, which it plans to use as part of a payment to members of a putative class in a related securities class action settlement.
Plaintiffs in the derivative cases will also seek court-approved attorneys’ fees of up to $2,250,000, which the company expects to be fully paid by insurance. A final approval hearing is scheduled for March 18, 2026, and the stipulation states there is no admission of liability by the defendants or the company.
Inotiv, Inc. reported that executive Andrea Castetter, EVP, General Counsel & Secretary, received a grant of 10,000 employee stock options. The options have an exercise price of $0.5956 per share and were awarded as a non-qualified stock option grant. According to the filing, the options vest over three years on a 40% / 30% / 30% schedule beginning on the first anniversary of the January 15, 2026 grant date, contingent on continued employment. After the grant, Castetter beneficially owns 10,000 stock options directly, and the options are scheduled to expire on January 15, 2036.